Efficacy and Safety of CDK4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER-2- ABC Patients: A Systematic Review and Meta-Analysis.
Cancer Invest
; 39(5): 369-378, 2021 May.
Article
em En
| MEDLINE
| ID: mdl-33886387
ABSTRACT
OBJECTIVE:
To evaluate the efficacy and safety of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors combined with endocrine therapy (ET) for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER-2-) advanced breast cancer (ABC) patients.METHODS:
We searched clinical trials of CDK4/6 inhibitors combined with ET and calculated the clinical outcomes.RESULTS:
HR+/HER-2- ABC patients treated with CDK4/6 inhibitors combined with ET had significantly prolonged progression-free survival (PFS) and improved objective response rate (ORR) and clinical benefit rate (CBR).CONCLUSIONS:
CDK4/6 inhibitors combined with ET can bring more clinical benefits to ABC patients, and the safety profile is acceptable.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Receptores de Progesterona
/
Receptores de Estrogênio
/
Quinase 4 Dependente de Ciclina
/
Quinase 6 Dependente de Ciclina
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article